Role of early PET in the management of diffuse large B-cell lymphoma

Current Opinion in Oncology

Volumn 22, Issue 5, 2010, Pages 414-418

  Michallet, Anne Sophie ^a   Trotman, Judith ^b   Tychyj Pinel, Christelle ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

complete remission; diffuse large B cell lymphoma; interim fluorine 18 fluorodeoxyglucose PET; prognostic marker

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

BIOPSY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG UPTAKE; HUMAN; LARGE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; REVIEW; TREATMENT RESPONSE;

HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS;

EID: 77955415713     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833d5905     Document Type: Review

References (26)

1. Buchmann I, Reinhardt M, Elsner K, et al. 2-(Fluorine-18)fluoro-2-deoxy- D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001; 91:889-899.
2. Hutchings M, Eigtved AI, Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 2004; 52:19-32.
3. Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85:613-618.
4. Kostakoglu L, Leonard JP, Coleman M, Goldsmith SJ. The role of FDG-PET imaging in the management of lymphoma. Clin Adv Hematol Oncol 2004; 2:115-121.
5. Weihrauch MR, Re D, Bischoff S, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002; 81:20-25.
6. Mikhaeel NG, Timothy AR, O'Doherty MJ, et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma 2000; 39:543-553.
7. Spaepen K, Stroobants S, Dupont P, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115:272-278.
8. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17:1244-1253.
9. Zinzani PL, Chierichetti F, Zompatori M, et al. Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation. Leuk Lymphoma 2002; 43:1239-1243.
10. Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004; 91:850-854.
11. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007; 110:3507-3516.
12. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429-433.
13. Spaepen K, Mortelmans L. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lym-phoma and Hodgkin's disease. Q J Nucl Med 2001; 45:269-273.
14. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglu-cose. Blood 1998; 91:4464-4471. (Pubitemid 28270292)
15. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13:1356-1363.
16. Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycleofchemotherapy in aggressive lymphoma and Hodgkin's disease.J Nucl Med 2002; 43:1018-1027.
17. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571-578.
18. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106:1376-1381.
19. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009; 27:1906-1914.
20. Querellou S, Valette F, Bodet-Milin C, et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol 2006; 85:759-767.
21. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37:181-200.
22. Jacene HA, Leboulleux S, Baba S, et al. Assessment of interobserver reproducibility in quantitative 18F-FDG-PET and CT measurements of tumor response to therapy. J Nucl Med 2009; 50:1760-1769.
23. Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009; 50:527-533.
24. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-586.
25. Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol 2010; 28:1896-1903.
26. Belakhlef A, Jani C, Church C, et al. Fat necrosis mimicking B-cell lymphoma: a PET/CT and FDG study. Clin Nucl Med 2008; 33:271-272